Beckley Psytech

Beckley Psytech is a clinical-stage biotechnology company focused on transforming psychedelics into effective, rapid-acting medicines for neuropsychiatric conditions. Dedicated to improving the lives of individuals facing these disorders, Beckley Psytech envisions integrating clinically validated psychedelic medicines into modern medical practice. This innovative approach aims to support patients living with depression and other profoundly debilitating neuropsychiatric conditions where there is a high unmet need.

Founded in 2019, Beckley Psytech leverages more than two decades of pioneering scientific research from the Beckley Foundation. The company combines world-leading psychedelic science with deep neuropsychiatric drug development expertise to optimize patient outcomes, improve treatment efficacy, and ease the burden these conditions place on individuals and society. Beckley Psytech is headquartered in Oxford, GB, driving forward advancements in mental health and pharmaceutical solutions.

With a focus on innovation and patient-centric solutions, Beckley Psytech continues to advance the field of psychedelic medicine. The company is committed to the highest standards of research and development, ensuring that its medicines meet the rigorous demands of modern healthcare. Beckley Psytech is actively expanding its capabilities and welcomes opportunities to collaborate with partners who share its vision. We invite the management team at Beckley Psytech to create a customized and exclusive company showcase and product listing on our platform to further highlight their groundbreaking work.